Long-term Prospective Study of Korean CADASIL Patients
NCT07497867 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2026-05-14
Summary
K-CADASIL is a 10-year prospective study of 500 Korean patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a genetic brain disease that causes stroke and dementia. The investigators will track symptoms, brain scans, memory tests, and gene information to understand disease progression in Koreans and identify better treatments. Participants will visit clinics regularly for check-ups and blood tests. This study aims to help improve care for CADASIL patients and families worldwide.
Conditions
- CADASIL
- Cerebral Autosomal Dominant Arteriopatie With Subcortical Infarcts and Leukoencephalopathy
Sponsors & Collaborators
-
Asan Medical Center
collaborator OTHER -
Chonnam National University Hospital
collaborator OTHER -
Chungbuk National University Hospital
collaborator OTHER -
Dong-A University Hospital
collaborator OTHER -
Ewha Woman University Medical Center
collaborator UNKNOWN -
Hallym University Medical Center
collaborator OTHER -
Hanyang University Seoul Hospital
collaborator OTHER -
Inje University Ilsan Paik Hospital
collaborator OTHER -
Kangdong Sacred Heart Hospital
collaborator OTHER -
Keimyung University Dongsan Medical Center
collaborator OTHER -
Korea University Ansan Hospital
collaborator OTHER -
Korea University Guro Hospital
collaborator OTHER -
Kyung Hee University Hospital
collaborator OTHER -
Kyungpook National University Hospital
collaborator OTHER -
Nowon Eulji Medical Center
collaborator OTHER -
Pusan National University Hospital
collaborator OTHER -
Seoul Medical Center
collaborator OTHER -
Seoul National University Bundang Hospital
collaborator OTHER -
Seoul National University Hospital
collaborator OTHER -
Severance Hospital
collaborator OTHER -
Soonchunhyang University Hospital
collaborator OTHER -
Ulsan University Hospital
collaborator OTHER -
Yeungnam University Hospital
collaborator OTHER -
Daejeon Eulji University Medical Center
collaborator OTHER -
Jeonbuk National University Hospital
collaborator UNKNOWN -
DongGuk University
collaborator OTHER -
Jeju National University Hospital
lead OTHER
Eligibility
- Min Age
- 19 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-07-10
- Primary Completion
- 2035-12-31
- Completion
- 2040-12-31
Countries
- South Korea
Study Locations
More Related Trials
-
Effect of Donepezil on the Reorganization of Cognitive Neural Network in Patients With Post-Stroke Cognitive Impairment
NCT00530478 ·Status: UNKNOWN ·Phase: NA
-
Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease
NCT07027072 ·Status: RECRUITING ·Phase: PHASE2
-
The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD
NCT01696591 ·Status: UNKNOWN
-
Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease
NCT02097056 ·Status: COMPLETED ·Phase: PHASE4
-
Korean Joint Registry for Alzheimer's Treatment and Diagnostics (JOY-ALZ)
NCT06889818 ·Status: RECRUITING
-
A Phase I [18F]THK-5351 Positron Emission Tomography Study in Healthy Subjects and Alzheimer's Disease
NCT03112096 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluating the Efficacy of Artificial Intelligence-based Computer Aided Diagnosis Software That Assists in Determining Whether or Not to Conduct Amyloid PET for the Diagnosis of Alzheimer's Disease by Predicting Amyloid PET Positivity in Mild Cognitive Impairment Patients
NCT05383053 ·Status: COMPLETED
-
Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjects With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's Disease
NCT03903211 ·Status: COMPLETED ·Phase: PHASE2
-
The Safety and The Efficacy Evaluation of NEUROSTEM®-AD in Patients With Alzheimer's Disease
NCT01297218 ·Status: COMPLETED ·Phase: PHASE1
-
Correlation Between Regional Brain Volume and Response to Donepezil Treatment in AD Patients
NCT00165750 ·Status: TERMINATED ·Phase: PHASE4
-
A Clinical Trial for an Evaluation of Choline Alfoscerate and Donepezil for Cognitive Improvements of Patients With Cerebrovascular Injury in Alzheimer Patients
NCT02648906 ·Status: UNKNOWN ·Phase: PHASE4
-
Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients
NCT01312363 ·Status: COMPLETED
-
An Observational Study of Patients Living With Chronic Neurological Diseases
NCT05796037 ·Status: NOT_YET_RECRUITING
-
A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular Disease
NCT02660983 ·Status: COMPLETED ·Phase: PHASE4
-
Assessment the Efficacy of Acetyl-L-carnitine in Patient With Alzheimer's Disease
NCT02955706 ·Status: COMPLETED ·Phase: PHASE4
-
A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease
NCT05811000 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Cilostazol Augmentation Study in Dementia
NCT01409564 ·Status: COMPLETED ·Phase: PHASE4
-
Olfactory Neuroepithelial Tissue of Alzheimer Disease
NCT02129452 ·Status: COMPLETED
-
BnH-015B Clinical Trial in Moderate Alzheimer's Disease
NCT06535308 ·Status: RECRUITING ·Phase: PHASE1
-
Prospective Cohort Study of Patients With Early Alzheimer's Disease Treated With Lecanemab
NCT06741553 ·Status: RECRUITING
-
GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)
NCT05303701 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Good Rate of Clinical Response to Cholinesterase Inhibitors in Alzheimer's Disease After Three Months of Treatment
NCT02007291 ·Status: COMPLETED
-
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease
NCT02899091 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease
NCT05811442 ·Status: COMPLETED ·Phase: PHASE2
-
Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM® Phase-I/IIa Clinical Trial.
NCT03172117 ·Status: COMPLETED ·Phase: PHASE1/PHASE2